Albert Schweitzer Ziekenhuis
Verified site
Dordrecht, The Netherlands
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
The study focuses on polycythemia vera, a rare blood condition where the bone marrow makes too many red blood cells, leading to thickened blood and an increased risk of clots. Participants who have not responded well to or cannot tolerate the standard medicine hydroxyurea may receive the investigational oral capsule called bomedemstat (code name MK-3543) or may continue with the best available therapy, which can include drugs such as ropeginterferon alfa-2b or ruxolitinib.
The purpose of the study is to compare how well the new drug works against the standard options in controlling blood counts and disease symptoms. Participants are randomly assigned to receive either the study drug or the chosen standard therapy, take the medication for several months, and attend regular clinic visits where blood tests and questionnaires are completed to monitor health.
Key outcomes include the clinicohematologic response, which means improvement in blood counts and disease signs, as well as safety measures such as any unwanted side effects, called adverse events, and the need for procedures like phlebotomy, which is the removal of blood to keep levels in a safe range. The study tracks these factors over time to see how long the benefits last and whether the disease progresses.
The trial runs in 9 steps – from screening to follow-up. Each step says what happens and what the team monitors.
10 criteria
7 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Dordrecht, The Netherlands
Madrid, Spain
Barcelona, Spain
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is an experimental oral capsule being tested as a new treatment for polycythemia vera. In this study it is given to participants who have not responded well to or cannot tolerate the standard drug hydroxyurea. Researchers are looking to see if bomedemstat can safely lower the number of red blood cells and improve blood counts compared with other available therapies.
is a medication that is injected under the skin. It belongs to a class of drugs called interferons, which help the immune system control abnormal blood cell production. In this trial it is used as an active comparator, meaning it serves as a known treatment against which the new drug bomedemstat is compared.
is an oral tablet that blocks specific enzymes (JAK1 and JAK2) involved in signaling pathways that cause excess blood cell growth. It is also used as an active comparator in the study, providing another established option for treating polycythemia vera so researchers can evaluate how bomedemstat performs relative to existing therapies.
This medication is taken by mouth as a hard capsule. It is still experimental and is being studied in clinical trials, not yet approved for general use. It is being tested for the treatment of polycythemia vera, a disease with too many red blood cells. It works by blocking the LSD1 enzyme, which helps reduce the abnormal growth of blood cells, and is classified as an LSD1 inhibitor (epigenetic modulator).
This drug is given as a subcutaneous injection, usually a small dose under the skin. It is approved in several countries for polycythemia vera and related blood disorders. It helps control the disease by acting like a natural interferon, signaling the body to lower the production of excess blood cells. It belongs to the class of pegylated interferons, which are immune‑modulating agents.
This medication is taken orally as a tablet, often at a dose of 50 mg. It is an approved treatment for polycythemia vera and related conditions. It reduces blood cell overproduction by blocking the JAK1 and JAK2 enzymes that send growth signals to blood cells. It is classified as a JAK inhibitor.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.